CMV Perils in Transplant Recipients: Prevention, Resistance, and Safety Considerations

Program Overview

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Credit Expired
0.75 CE Credit(s)
Expires: November 8, 2022

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
  • Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Faculty

Camille Kotton portrait 2021

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Chemaly 500x500

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ

Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX

SILVEIRA_FERNANDA_MD_ID_20180124

Fernanda P. Silveira, MD, MS, FIDSA, FAST

Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources